News

The assistant professor of pediatric neurology at Washington University in St. Louis provided an overview of cerebral palsy and ways to reduce the risk of developing the condition. [WATCH TIME: 3 minutes]

Infection-related epilepsy etiology, experiencing multiple types of seizures, and cognitive impairment were independent influencing factors on perampanel use retention.

The William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology, and Neurologist-in-Chief at Yale-New Haven Hospital spoke to the findings of a recent assessment of T cells in multiple sclerosis. [WATCH TIME: 4 minutes]

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

Data provide an update to the post-approval safety profile of cladribine tablets in patients with relapsing MS in reference to COVID-19 infections.

Investigators also found that this association was particularly pronounced among those living in nursing homes, as well as in Asian, Black, and Hispanic populations.

Leigh Charvet, PhD, professor of neurology, NYU Grossman School of Medicine, discussed the potential feasibility of at-home tDCS for patients with multiple sclerosis to boost cognitive training. [WATCH TIME: 2 minutes]

The neurodegeneration program lead at Genentech offered his perspective on the phase 3 SKYLINE trial and the historical data on gantenerumab ahead of this new clinical assessment.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.

More than half of the patients with episodic migraine considered the likelihood of migraine on day 1 postdosing to be as important as the reduction in migraines in the days to follow.

With the Parkinson’s Foundation recently being granted Joint Accreditation and announcing a new and free CME course, James Beck, PhD, senior vice president and chief scientific officer of the organization, commented on the pivotal role genetic testing can play.

Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed her presentation at ACTRIMS Forum 2022 involving imaging biomarkers of RIS/MS prodrome. [WATCH TIME: 4 minutes]

Factors such as fear of negative consequences, attention and anticipation, and fear-avoidances were identified using the newly developed Fear of Attacks in Migraine Inventory questionnaire, which may have use in clinical settings.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers and clinical professor of neurology at UCLA spoke to the importance of understanding the challenges specific to women with Parkinson disease. [WATCH TIME: 8 minutes]

Here's what is coming soon to NeurologyLive®.

Mobile stroke units led to a higher proportion of intravenous thrombolysis among patients with acute ischemic stroke, of whom up to one-third were treated within 60 minutes of symptom onset.

The senior vice president and chief scientific officer of the Parkinson’s Foundation spoke on the initiative, which offers free genetic testing and counseling for patients with Parkinson disease. [WATCH TIME: 2 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is nutrition in multiple sclerosis.

A third dose enhanced the number of responders to all variants and significantly increased CD8 T-cell responses, but the frequencies of Omicron-specific CD8 T-cells remained 70% of the responses specific to the vaccine strain.

Data were analyzed from the AFFINITY study cohort, which included men and women recruited within 2 weeks of stroke onset in Australia, New Zealand, and Vietnam.

Results from the preliminary study investigating the safety of the ketogenic diet for patients with MS were announced ahead of the AAN Annual Meeting in April 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 4, 2022.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research discussed the results of a new study on age and sex as determinants of autoimmune encephalitis. [WATCH TIME: 3 minutes]

Nine of 15 tested patients in the intrathecal stem cell group had a reduction of more than 50% in neurofilament light levels, compared with only 1 of 15 in the placebo group.

The senior vice president and chief scientific officer of the Parkinson’s Foundation outlined the new CE course, as well as the benefits of being granted Joint Accreditation. [WATCH TIME: 4 mintues]

The trial will use PACC-5 score as its primary end point and expects to enroll 1200 participants who have confirmed amyloid pathology without signs of cognitive impairment.

The treatment is being developed as a first-in-class regenerative therapy for those with AD and dementia, with these safety data offering support to its development.

Investigators noted the need for more transformational treatments to improve disability for patients with both primary and secondary progressive multiple sclerosis.

The vascular neurologist at Allegheny Health Network discussed ways to grow the RapidAI software and the need to conduct additional, large-scale research. [WATCH TIME: 3 minutes]